PRCT in Q1 2026: Revenue Advances Meet Roadmap Realignment, A Quiet Lesson in Medical Robotics

Lead takeaways from Procept BioRobotics’ first quarter of 2026

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) reported a solid top line for the quarter, with Total revenue of $83.1 million, up 20% year over year. The U.S. business accounted for the majority, delivering $72.0 million in revenue—up 19%—driven by a combination of system sales and consumables. Within the U.S., handpieces contributed $43.0 million (up 13%) and system revenue was $23.4 million (up 25%). International revenue was $11.1 million, rising 25%.

The upbeat top line sits atop a bottom line that remains in the red: net loss of $31.6 million, versus a $24.7 million loss in the prior year period. Adjusted EBITDA was a loss of $18.1 million. In other words, earnings per share (EPS) remains negative for now, and the market will keep a keen eye on how investors weight the EPS consensus versus actual results as the company progresses along its profitability path.

Margins, mix, and the cost side of growth

The gross margin stood at approximately 65% for the quarter, a slight uptick from 64% a year ago and above the 61% reported in Q4 2025. The delta was driven by revenue mix and pricing, partially offset by inventory capitalization and tariff costs.

Operating expenses totaled $86.6 million, up from $71.6 million in the prior year, reflecting continued investment to support commercial expansion, ongoing innovation across the BPH platform, and funding for the WATER IV Prostate Cancer trial. The result is a narrative of growth investments weighing on near-term profitability—an outcome not surprising given the strategic reset underway.

Product momentum and strategic milestones

A key milestone was FDA clearance of the second-generation FirstAssist AI software, which enhances Aquablation planning with AI-assisted imaging and planning. Management frames this as a step that strengthens the HYDROS robotic platform by enabling more precise anatomy identification and more consistent treatment planning.

The company emphasizes its ongoing pivot toward a software-enabled, AI-assisted, image-guided approach, with a continued emphasis on a combined hardware-plus-service/consumables model. Notably, the U.S. installed base ended March 31, 2026 at 765 systems, up about 40% year over year, illustrating meaningful adoption despite the transitional headwinds.

Quants and customer adoption signals

• First-quarter 2026 U.S. Aquablation procedures: approximately 12,200.
• Hydros system sales in the U.S.: 49, including 2 replacement systems.
• U.S. handpieces as a percentage of U.S. procedures: about 95%.
• First-quarter 2026 handpiece average selling price: about $3,500, up roughly 5% versus Q4 2025.
• New Hydros systems ASP: about $485,000.

The international business contributed $11.1 million, continuing its double-digit rebound alongside U.S. growth, reinforcing a diversified revenue base outside the domestic market.

Cash position and near-term liquidity

The company reported cash, cash equivalents, and restricted cash balances around $249 million as of March 31, 2026, providing a cushion for ongoing R&D, regulatory work, and commercial expansion as profitability remains a work in progress.

What this portends for PRCT and peers

The Q1 2026 results consolidate a theme prevalent in specialty medical device growth stories: topline expansion driven by procedure mix and price with a cost structure still recalibrating post-realignment. The approval of the Second-generation FirstAssist AI software signals a broader shift toward AI-assisted planning in robotic urology, a development that could compress cycle times, elevate surgeon confidence, and potentially drive higher utilization in the HYDROS platform.

For PRCT, the path to meaningful EPS improvement hinges on sustaining the revenue momentum while containing operating expenses and realizing scale benefits from faster adoption. The EPS consensus will be a litmus test for whether investors view the current losses as a necessary investment phase or a warning sign of structural cost headwinds. In the near term, a higher revenue forecast trajectory—particularly as international growth accelerates and the company monetizes more consumables per procedure—could set the stage for a more balanced P&L.

Sector peers will watch PRCT’s mix shift and its ability to translate procedural volume into durable gross margins. A 65% gross margin at scale is plausible if price realization and supply-chain discipline persist, but the expense ramp required to sustain growth—especially in clinical trials and regulatory pathways—will test investor patience. If PRCT can convert the current top-line strength into steady, positive free cash flow, it could lift the broader robotics and surgical platforms space, encouraging peers to accelerate AI-enabled enhancements and to push for higher-pricing power on consumables.

Outlook and takeaways

The quarter underscores a strategic crossroad: growth investment and realignment versus profitability timetables. The early signs—strong U.S. demand, expanding install base, and FDA-cleared AI software—provide a constructive backdrop for converting revenue gains into improved margins over time. For PRCT, the next several quarters will be telling on whether the company can convert gains in system and handpiece revenue into meaningful operating leverage and a positive EPS trajectory.

As the sector increasingly rhymes with AI-enabled precision medicine, investors should keep an eye on a few proxies: the progression of the international revenue mix, the pace of AI software adoption, and the company’s ability to manage a higher fixed-cost structure while expanding the installed base. In other words, the real surgical precision may lie in whether PRCT can deliver a favorable revenue forecast while trimming red ink on the bottom line—an outcome that would reverberate through its cohort and potentially lift the entire field of robotic urology.

Bottom line

Q1 2026 reinforces PRCT’s capability to grow revenue and expand its installed base, while reminding investors that profitability remains dependent on execution and pace of cost optimization. The FDA clearance for AI-assisted planning and a rising U.S. and international demand backdrop provide a reason to stay constructive, even as EPS remains negative for now. If the company can translate the top-line momentum into durable gross margin expansion and controlled operating expenses, the equity story for PRCT—and perhaps for its peers—could move from a cut-and-paste growth narrative to a more sustainable, repeatable profitability thesis.